Posted: 13 November 2025
Lindo has been awarded $2 million in matched funding through the Australian Government’s Industry Growth Programme, enabling progress on its antimicrobial blue-light endotracheal device. “Collaborations like this are essential for translating innovation into practical medical solutions,” said Robert Gangi, CEO and Founder of Lindo. The investment supported a total project value of $4 million and was directed toward lifting the Lindo Tube from Technology Readiness Level 4 to 7, preparing it for preclinical and clinical studies in Australia and the United States.
The funding had been secured to accelerate development of an endotracheal tube embedded with antimicrobial blue light technology, designed to eliminate harmful bacteria within ventilator circuits and reduce the risk of ventilator-associated pneumonia. The project was underpinned by a know-how licence agreement with Mayo Clinic, with Lindo Life Science working with clinicians in Jacksonville, Florida to refine the proof of concept.
Development of the Lindo Tube was undertaken with several Australian and international partners, including Marker Design, Sento Solutions, Eleven Borders, Spectral Blue, and Monash University’s Centre to Impact Antimicrobial Resistance. Their combined expertise in engineering, design, usability, regulatory strategy, and translational research was applied to support the device’s pathway to commercial readiness.
Under the project, key activities were carried out to finalise and scale the prototype, conduct usability and workflow studies, engage early with the US Food and Drug Administration and Australia’s Therapeutic Goods Administration, strengthen intellectual property and quality systems, and build domestic manufacturing capability. Delivered entirely in Australia, the initiative was expected to generate more than 50 jobs across research, development, regulatory functions, and advanced manufacturing.
The Lindo Tube targets a global market valued at over USD 450 million, with initial commercial focus on the United States followed by Asia Pacific and European expansion. The grant represents a significant milestone in Lindo’s effort to deliver science-based infection-prevention technologies and highlighted the role of strategic partnerships in strengthening sovereign medical device innovation.
